Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648616 | 0.87 | KDM4E (0.71) | SMN1; SMN2L3MBTL1KDM4EABL1LMNA | |
| SCHEMBL16803444 | 0.84 | SMN1; SMN2 (0.61) | HPGDSMN1; SMN2L3MBTL1KDM4EABL1 | |
| SCHEMBL326931 | 0.84 | L3MBTL1 (0.58) | L3MBTL1TDP1 | |
| SCHEMBL3188250 | 0.84 | SMN1; SMN2 (0.67) | HPGDSMN1; SMN2L3MBTL1KDM4EABL1 | |
| SCHEMBL16648622 | 0.84 | POLB (0.58) | HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL10174320 | 0.84 | USP30 (0.57) | L3MBTL1KMT2A | |
| SCHEMBL32678039 | 0.83 | USP30 (0.56) | L3MBTL1KMT2A | |
| SCHEMBL32678038 | 0.83 | USP30 (0.56) | L3MBTL1KMT2A | |
| SCHEMBL16648680 | 0.83 | HRH3 (0.54) | L3MBTL1KDM4E | |
| SCHEMBL16769729 | 0.83 | KDM4E (0.76) | HPGDSMN1; SMN2L3MBTL1KDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081566-B1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9796709-B2 | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20160376267-A1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| EP-3081566-A1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2016-10-19 | — | — | EP | disclosed |
| EP-2048132-B1 | Tetrahydro-naphthalene and urea derivatives | XENTION LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| EP-2048132-A1 | Tetrahydro-naphthalene and urea derivatives | Xention Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-1670761-B1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | XENTION LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1670761-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005040119-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376267-A1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | LDLR, LCAT, LPL | HPGD 1125/4885SMN1; SMN2 1896/4885L3MBTL1 511/4885 |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | NQO2, UGT1A4, CYP4B1 | HPGD 264/4885SMN1; SMN2 2528/4885L3MBTL1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.